About biodesix inc - BDSX
Biodesix, Inc. operates as a diagnostic solutions company. It engages in providing blood-based diagnostic tests and development services. The firm offers five diagnostic tests, including Nodify CDT, Nodify XL2, GeneStrat ddPCR, GeneStrat NGS, and VeriStrat. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.
BDSX At a Glance
Biodesix, Inc.
919 West Dillon Road
Louisville, Colorado 80027
| Phone | 1-303-417-0500 | Revenue | 88.50M | |
| Industry | Medical/Nursing Services | Net Income | -35,265,000.00 | |
| Sector | Health Services | 2025 Sales Growth | 24.082% | |
| Fiscal Year-end | 12 / 2026 | Employees | 334 | |
| View SEC Filings |
BDSX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.58 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.742 |
| Enterprise Value to Sales | 1.188 |
| Total Debt to Enterprise Value | 0.693 |
BDSX Efficiency
| Revenue/Employee | 264,967.066 |
| Income Per Employee | -105,583.832 |
| Receivables Turnover | 9.794 |
| Total Asset Turnover | 0.937 |
BDSX Liquidity
| Current Ratio | 1.865 |
| Quick Ratio | 1.79 |
| Cash Ratio | 1.095 |
BDSX Profitability
| Gross Margin | 75.248 |
| Operating Margin | -31.374 |
| Pretax Margin | -39.848 |
| Net Margin | -39.848 |
| Return on Assets | -37.347 |
| Return on Equity | -383.086 |
| Return on Total Capital | -50.10 |
| Return on Invested Capital | -46.668 |
BDSX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 103.502 |
| Total Debt to Total Assets | 81.242 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 101.556 |